Search the Newsreel

Diodes adds former executive Evan Yu to board By Investing.com

Diodes Incorporated (NASDAQ:DIOD) has appointed former Senior Vice President of Worldwide Power Products, Evan Yu, to its board of directors, effective August 1, 2026. Yu's extensive background includes leadership roles at Diodes, CEO of Commit Inc., and 15 years at Texas Instruments, making his …

Live webcast set for AngioDynamics' Aug. 11 presentation

AngioDynamics, Inc. announced its management team will participate in upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026. A live webcast of the Canaccord …

Diodes Incorporated Elects Evan Yu to the Board as Independent Director, Effective August 1, 2026

Diodes Incorporated has announced the election of Evan Yu to its Board of Directors, effective August 1, 2026. Yu, a seasoned global semiconductor executive with extensive leadership experience in various technologies and international markets, previously served as Senior Vice President of Worldwide Power Products …

Biodesix Market Sentiment

This article analyzes market sentiment for Biodesix (BDSX) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts with varied price targets and details recent analyst actions including upgrades, downgrades, and initiations. The article also mentions …

Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Biodesix Inc (BDSX) Income Statement

This article provides the quarterly and annual income statements for Biodesix Inc. (BDSX), detailing financial performance metrics such as total revenue, operating expenses, and net income from Q3 2020 through Q1 2026. It also includes frequently asked questions about understanding and analyzing the company's …

Biodesix Inc (BDSX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Biodesix Inc.'s (BDSX) shareholder structure, detailing major individual and institutional holdings. Key shareholders include Jack W. Schuler and Lawrence T. Kennedy Jr., alongside institutional holdings from various investment types. The data also presents historical institutional shareholding trends and …

Diodes Inc (DIOD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Diodes Inc (DIOD), listing its major institutional holders and their respective proportions. It also presents a breakdown of shareholder types, institutional shareholding over recent quarters, and changes in stakes by key investors. Additionally, the article highlights several …

AngioDynamics Inc (ANGO) Balance Sheet

This article provides key balance sheet information for AngioDynamics Inc (ANGO), including quarterly and annual data for various assets, liabilities, and shareholders' equity components. It allows users to evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. The data highlights recent …

Biodesix Inc (BDSX) Cash Flow

This article provides detailed annual and quarterly cash flow statements for Biodesix Inc (BDSX), allowing investors to evaluate the company's financial health. It breaks down operating, investing, and financing cash flows, along with changes in working capital and capital expenditures. The report also includes …

Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Biodesix Inc (BDSX), noting its current valuation score of 8.53, ranking 32nd in the Healthcare Providers & Services industry. It details the company's P/E ratio of -5.31, which is significantly below its recent high and above its …

IODM (ASX:IOD) Gains 6%—Can Receivables Technology Support a Recovery?

AngioDynamics Inc (ANGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for AngioDynamics Inc (ANGO) as of April 6. It shows that the majority of its revenue (85.79%, or $67.28M) comes from the United States, with 14.21% ($11.14M) from international regions. The article notes that relevant data for business …

Biodesix Inc (BDSX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a historical overview of dividends and stock splits for Biodesix Inc (BDSX). It states that the company has distributed $0.00 in dividends over the past five years. The only recorded stock split event is a 20-to-1 merger scheduled for September 11, …

AngioDynamics Inc

AngioDynamics Inc (ANGO) is a medical technology company focused on vascular health and cancer treatment. The company designs, manufactures, and sells devices for vascular access, peripheral vascular disease, oncology, and surgical settings. Its product categories include oncology, venous therapies, vascular interventions, and ports, utilized …

Dimensional Fund Advisors LP Acquires 53,934 Shares of Diodes Incorporated $DIOD

Dimensional Fund Advisors LP increased its stake in Diodes Incorporated by 2.3% in the first quarter, acquiring an additional 53,934 shares to own a total of 2,436,359 shares valued at $166.29 million. Other institutional investors also adjusted their positions in DIOD, with 99.23% of …

Diodes Incorporated Revenue Breakdown – NASDAQ:DIOD

Diodes Incorporated (NASDAQ: DIOD) generated $1.48 billion USD in revenue last year, with its Distributor segment contributing the most at $959.71 million USD. The majority of its revenue, $900.51 million USD, came from the Asia region. The company's financial performance shows growth in its …

Diodes Inc (DIOD) Institutional Confidence

Diodes Inc (DIOD) has an institutional shareholding score of 10.00, placing it first among 105 companies in the Semiconductors & Semiconductor Equipment industry. The institutional shareholding proportion is 99.15%, though it experienced a 9.69% decrease quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 944.10K …

AngioDynamics (NASDAQ: ANGO) CEO settles performance share grant

AngioDynamics (NASDAQ: ANGO) CEO James C. Clemmer settled a performance share grant from 2023, receiving 52,358 shares of Common Stock. The original grant of 184,361 units was based on multi-year performance metrics, with the remaining units forfeited. To cover tax withholding obligations, 26,728 shares …

AngioDynamics Inc (ANGO) CFO performance shares vest, tax withheld

AngioDynamics Inc. CFO Stephen A. Trowbridge received 16,296 shares of common stock from the vesting of performance share units, which were part of a target grant of 57,381 units on July 19, 2023. The shares vested based on performance metrics and relative total shareholder …

AngioDynamics (ANGO) SVP receives shares from PSU vesting, with tax withholding

Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics (ANGO), received 6,466 shares of common stock from the vesting of performance share units, which were originally granted on July 19, 2023. To cover tax withholding obligations, 2,330 shares were disposed of at $13.82 per share. …

AngioDynamics (NASDAQ: ANGO) executive settles 20,052 performance units

Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics (NASDAQ: ANGO), had a 2023 performance share unit grant settle, resulting in 5,694 shares of common stock being issued from a target of 20,052 units. The remaining units were forfeited, and 1,671 shares were withheld …

AngioDynamics Inc. (ANGO) SVP receives 8,047 shares, 4,506 withheld for tax

AngioDynamics Inc.'s SVP International, Laura Piccinini, received 8,047 common shares from the vesting of performance share units granted in July 2023. Of these, 4,506 shares were withheld for tax obligations at $13.82 per share, and the remaining 20,289 units from the original grant were …

Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Biodesix Inc (BDSX), noting its current financial score is 7.18, ranking 52 out of 75 in the Healthcare Providers & Services industry, indicating a weak financial status but average operating efficiency. The company recently reported a 42.30% …

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

The article compares bioAffinity Technologies (BIAF) and Biodesix (BDSX), two cancer diagnostics companies. While BIAF specializes in non-invasive lung cancer diagnostics and is in an earlier commercial stage with higher risk, BDSX has a more established commercial portfolio and diversified revenue streams through its …

BDSX|Biodesix Inc|Price:22.000|Chg%:-0.320

Biodesix Inc (BDSX) closed at $22.00, down 1.43%, with a market cap of $222.36 million. Analysts rate the stock as a "Buy" with a target price of $28.75, implying a potential 28.81% upside. The company shows strong fundamentals and high growth potential, despite recent …

AngioDynamics Inc. (ANGO) awards 17,966 RSUs and performance rights

AngioDynamics Inc. (ANGO) has granted its SVP of Quality and Regulatory, Warren Nighan Jr., 17,966 restricted stock units (RSUs) and 17,966 performance rights. The RSUs will vest in four equal annual installments from July 2027 to 2030, while the performance rights are tied to …

AngioDynamics (ANGO) awards director Michael Tarnoff 11,887 shares

AngioDynamics director Michael E. Tarnoff received a grant of 11,887 shares of common stock on July 15, 2026. These shares were awarded as restricted stock units for regular annual director compensation and vested immediately upon grant. Following this transaction, Tarnoff directly holds 95,265 common …

AngioDynamics Inc. (ANGO) awards 11,887 RSUs to board director

AngioDynamics Inc. (ANGO) director Wesley Johnson was granted 11,887 restricted stock units (RSUs) on July 15, 2026, as part of his regular annual compensation for board service. These RSUs vested immediately, increasing his direct holdings to 155,425 common shares. The award was processed at …

AngioDynamics (NASDAQ: ANGO) grants RSUs and performance rights to legal chief

AngioDynamics (NASDAQ: ANGO) has granted 21,288 restricted stock units (RSUs) and 21,288 performance rights to its SVP and Chief Legal Officer, Lawrence T. Weiss. The RSUs will vest in four equal annual installments from 2027 to 2030, while the performance rights are tied to …

AngioDynamics Inc (ANGO) director awarded 11,887 shares in annual grant

AngioDynamics Inc. director Howard W. Donnelly was granted 11,887 shares of common stock on July 15, 2026, as part of his regular annual compensation for board service. These shares, representing restricted stock units, vested immediately, increasing his direct holdings to 178,938 shares. This transaction …

RSU grant lifts AngioDynamics Inc. (ANGO) director to 116,921 shares

AngioDynamics Inc. director Jan Stern Reed was granted 11,887 restricted stock units (RSUs) on July 15, 2026, as regular annual compensation for board service. These RSUs immediately vested, increasing Reed's direct holdings to 116,921 common shares. The transaction, reported at $0.00 per share, was …

AngioDynamics (ANGO) director receives 11,887-share stock award

AngioDynamics Inc. (ANGO) director Karen A. Licitra was granted 11,887 shares of common stock on July 15, 2026, as regular annual compensation for her board service. These restricted stock units immediately vested upon grant, increasing her direct holdings to 102,322 shares. The transaction, reported …

AngioDynamics (ANGO) director granted 11,887 immediately vested RSUs

AngioDynamics Inc. director Auen Eileen O'Shea was granted 11,887 restricted stock units (RSUs) as part of her regular annual compensation. These RSUs, which represent 11,887 shares of common stock, vested immediately, increasing her direct holdings to 116,605 shares. The transaction, filed as a Form …

Biodesix to report Q2FY26 results on August 5, 2026

Biodesix, Inc., a diagnostic solutions company specializing in lung disease, announced it will release its financial results for the second quarter ended June 30, 2026, after the close of trading on August 5, 2026. The company will also host a conference call and webcast …

Biodesix management will give a business update on Aug. 5

Biodesix (Nasdaq: BDSX) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss results and provide a business …